Validation Data Gallery
Tested Applications
| Positive WB detected in | K-562 cells, RAW264.7 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 1 publications below |
Product Information
17420-1-AP targets CSGALNACT2 in WB, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag11436 Product name: Recombinant human CSGALNACT2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 195-542 aa of BC030268 Sequence: DEDDEQEDEEGPLGEKLIFNENDFVEGYYRTERDKGTQYELFFKKADLTEYRHVTLFRPFGPLMKVKSEMIDITRSIINIIVPLAERTEAFVQFMQNFRDVCIHQDKKIHLTVVYFGKEGLSKVKSILESVTSESNFHNYTLVSLNEEFNRGRGLNVGARAWDKGEVLMFFCDVDIYFSAEFLNSCRLNAEPGKKVFYPVVFSLYNPAIVYANQEVPPPVEQQLVHKKDSGFWRDFGFGMTCQYRSDFLTIGGFDMEVKGWGGEDVHLYRKYLHGDLIVIRTPVPGLFHLWHEKRCADELTPEQYRMCIQSKAMNEASHSHLGMLVFREEIETHLHKQAYRTNSEAVG 相同性解析による交差性が予測される生物種 |
| Full Name | chondroitin sulfate N-acetylgalactosaminyltransferase 2 |
| Calculated molecular weight | 542 aa, 63 kDa |
| Observed molecular weight | 63-70 kDa |
| GenBank accession number | BC030268 |
| Gene Symbol | CSGALNACT2 |
| Gene ID (NCBI) | 55454 |
| RRID | AB_2083878 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q8N6G5 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
CSGALNACT2 (Chondroitin Sulfate N-Acetylgalactosaminyltransferase 2) is a glycosyltransferase localized to the Golgi membrane that catalyzes the transfer of N-acetylgalactosamine (GalNAc) from the donor substrate UDP-GalNAc to the non-reducing end of glucuronic acid (GlcUA) on growing glycosaminoglycan chains. Increased expression of CSGALNACT2 has been observed in the arterial wall during the progression of atherosclerosis, contributing to the elongation of CS chains that may promote lipid retention and smooth muscle cell migration.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CSGALNACT2 antibody 17420-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |